Skip to main content
TipRanks
Go Ultimate75% OFF

Orthofix Medical (OFIX) AI Stock Analysis

94 Followers
OFIX

Orthofix Medical

(NASDAQ:OFIX)

Select Model
Rating:44Neutral
Price Target:$7.00▲(4.95% Upside)
Action:reiterated
Date:11/11/26

OFIX scores low primarily due to weak cash flow (deeply negative TTM free cash flow) and continued net losses despite improving revenue growth and EBITDA margins. Technicals also weigh on the score given the stock’s sharp underperformance versus key moving averages and negative MACD. Earnings-call commentary is mixed—guidance was reduced and 2027 faces an MDR headwind—partially offset by segment strength (Therapeutic Solutions and limb reconstruction) and ongoing profitability improvement.

Positive Factors
Revenue and margin improvementStrong revenue growth alongside higher EBITDA margins indicates improving operating leverage and better execution. Although profitability is not complete, the combination of scale and cost discipline can strengthen earnings capacity and provide a more durable foundation for future investment.
Negative Factors
Persistent cash burnDeeply negative free cash flow means the business is not currently self-funding despite improving revenue and EBITDA. Continued investment or working-capital needs may require external financing or constrain strategic flexibility until cash conversion improves consistently.

Orthofix Medical Key Performance Indicators (KPIs)

Revenue by SegmentBreaks down sales across Orthofix’s business lines (such as spinal products, orthopedics, and adjunct therapies), showing which products or segments are driving growth and which are lagging. Understanding the segment mix helps assess diversification, dependency on key product areas, and how new launches or acquisitions could shift future revenue.

$0.00$50.00M$100.00M$150.00M$200.00MMar 21Jun 21Sep 21Dec 21Mar 22Jun 22Sep 22Dec 22Mar 23Jun 23Sep 23Dec 23Mar 24Jun 24Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25Mar 26Jun 26
Chart Insights

Since early‑2023 Global Spine has been the clear growth engine—sales stepped up materially and remain the dominant contributor—while Global Orthopedics, though much smaller, has shown steady acceleration through 2024–25. Management attributes momentum to prioritized distributor relationships, better field execution and upcoming product launches (TrueLok Elevate, Fitbone, VIRATA), which underpin the reaffirmed 2026 guidance. Watch points: lingering biologics softness, timing/stocking variability and modest near‑term EBITDA/cash generation (plus legal settlement risk) could limit upside despite spine strength.

Data provided by:The Fly

Orthofix Medical (OFIX) vs. SPDR S&P 500 ETF (SPY)

-60%-40%-20%0%20%OFIX-53.32%SPY+11.73%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$271.87M
Dividend Yield
―
Average Volume (3M)
473.89K
Price to Earnings (P/E)
-6.0
Beta (1Y)
0.89
Revenue Growth
2.12%
EPS Growth
63.59%
Country
US
Employees
1,605
Sector
Healthcare
Sector Strength
51
Industry
Medical - Devices

Orthofix Medical Business Overview & Revenue Model

Company Description

Orthofix Medical Inc., founded in 1980 and headquartered in Lewisville, Texas, operates as a global medical technology company focusing on devices and biologics. Its reach extends across the United States, several European nations including Italy, Ge...

How the Company Makes Money

Orthofix makes money primarily by selling medical devices and related implants/biologics used in spine and orthopedic procedures and bone-healing therapies. Key revenue streams typically include: (1) Spine hardware and enabling technologies: revenue...

Orthofix Medical Earnings Call Summary

Earnings Call Date:Nov 09, 2026(Q3-2026)|% Change Since:-15.25%|Next Earnings Date:Feb 19, 2027
Earnings Call SentimentNeutral

The call presented a mixed outlook. Limb Reconstruction, Therapeutic Solutions, Biologics stabilization, technology launches and improved adjusted EBITDA were positive, but these were offset by below-expectation results, U.S. Spine weakness, supplier and instrument constraints, reduced 2026 guidance, unfavorable mix, cash timing pressure and a stated 2027 MDR revenue headwind.

Positive Updates

Quarterly Revenue Increased
Third quarter reported net sales were $207.9 million, an increase of 2.3% year-over-year. Growth in limb reconstruction and Therapeutic Solutions helped offset weaker Spine performance.

Negative Updates

Third-Quarter Results Were Below Expectations
Management stated that third-quarter results were below expectations, with U.S. Spine affected by market softness, unplanned supplier delays, inventory constraints and instrument set constraints.

Company Guidance

Orthofix now expects full year 2026 pro forma net sales in the range of $825 million to $830 million and full year 2026 non-GAAP adjusted EBITDA of $86 million to $88 million, with the outlook provided on a non-GAAP pro forma basis, reflecting current foreign currency exchange rates and excluding the discontinued M6 product lines. For the fourth quarter, the company expects sequential growth from normal seasonality and inventory purchases under the European distributor arrangement, with most of the approximately $15 million 2026 net sales benefit expected in the fourth quarter. The European MDR strategy for Spine is expected to create an approximately $22 million net sales headwind in 2027, while MDR requirements are completed. The company is not providing full guidance on 2027, but expects Therapeutic Solutions and limb recon to show above-market growth, core revenue to be in the positive territory backing out the MDR, and Q3, Q4 performance to continue into 2027; core distributors’ growth slowed to the mid-single digits.

Orthofix Medical Financial Statement Overview

Summary

Operational trends are improving (TTM revenue up 26.7%, strong ~69% gross margin, EBITDA margin improved to ~11.5%), but the company remains loss-making (negative operating profit and ~-5.4% net margin). Balance sheet leverage has risen (~0.55x debt/equity) and free cash flow is deeply negative (about -$43.7M TTM), making cash burn and incomplete profitability the key constraints.

Income Statement

46Neutral

Balance Sheet

57Neutral

Cash Flow

34Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue835.41M822.31M799.49M746.64M460.71M464.48M
Gross Profit577.83M551.71M545.88M486.27M337.17M349.56M
EBITDA95.34M9.93M-18.28M-79.49M15.66M21.44M
Net Income-45.00M-92.19M-126.00M-151.40M-19.75M-38.38M
Balance Sheet
Total Assets855.76M850.65M893.29M925.32M458.63M476.62M
Cash, Cash Equivalents and Short-Term Investments86.32M82.03M83.24M33.11M50.70M87.85M
Total Debt234.85M229.26M179.63M117.07M21.53M24.31M
Total Liabilities426.19M400.61M390.17M326.58M121.77M139.69M
Stockholders Equity429.57M450.04M503.12M598.73M336.86M336.93M
Cash Flow
Free Cash Flow-43.67M-1.28M-9.09M-107.80M-34.70M-1.12M
Operating Cash Flow5.01M33.35M25.79M-45.75M-11.54M18.48M
Investing Cash Flow-48.53M-34.60M-27.58M-33.13M-24.53M-23.01M
Financing Cash Flow65.73M-786.00K50.71M65.32M-78.00K-3.62M

Orthofix Medical Technical Analysis

Technical Analysis SentimentNegative
Last Price6.67

Price Trends

50DMA8.97Negative
100DMA9.81Negative
200DMA10.75Negative

Market Momentum

MACD-0.71Positive
RSI29.69Positive
STOCH10.23Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OFIX, the sentiment is Negative. The current price of 6.67 is below the 20-day moving average (MA) of 8.61, below the 50-day MA of 8.97, and below the 200-day MA of 10.75, indicating a bearish trend. The MACD of -0.71 indicates Positive momentum. The RSI at 29.69 is Positive, neither overbought nor oversold. The STOCH value of 10.23 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for OFIX.

Orthofix Medical Risk Analysis

Orthofix Medical disclosed 54 risk factors in its most recent earnings report. Orthofix Medical reported the most risks in the "Legal & Regulatory" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Legal & Regulatory - Litigation, compliance, new legislation, and taxation risks

Latest Risks Added

3 New Risks
1.The U.S. Food and Drug Administration's ("FDA") reclassification of bone growth stimulator devices from Class III to Class II may increase competition and adversely affect our future sales.Q3, 2026
2.The U.S. Food and Drug Administration's ("FDA") reclassification of bone growth stimulator devices from Class III to Class II may increase competition and adversely affect our future sales.Q1, 2026
3.We continue to integrate legacy businesses that operate in different market segments, and we may not be able to achieve all of our intended synergies between such legacy businesses.Q4, 2025

Orthofix Medical Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

OFIX against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
GMEDGMED73Outperform$9.27B16.9911.82%―13.35%32.22%
SIBNSIBN70Outperform$1.04B-74.61-7.57%―13.99%39.54%
BVSBVS66Neutral$893.17M12.4227.23%―3.87%623.68%
ENOVENOV58Neutral$1.57B-2.97-35.53%―3.28%62.02%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
ATECATEC50Neutral$1.08B-12.34-547.17%―15.34%46.31%
OFIXOFIX44Neutral$271.87M-5.99-10.32%―2.12%63.59%

* Healthcare Sector Average

Performance Comparison

-50%0%50%100%OFIXATECENOVGMEDSIBNBVSDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
OFIX and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
OFIXOrthofix Medical Inc.6.67-7.79-53.87%
ATECAlphatec6.94-12.68-64.63%
ENOVEnovis Corporation27.220.050.18%
GMEDGlobus Medical69.99-13.83-16.50%
SIBNSi-Bone23.164.5624.52%
BVSBioventus, Inc.10.603.8857.74%

Orthofix Medical Corporate Events

Business Operations and StrategyFinancial Disclosures

Orthofix Reports Third-Quarter Sales Growth and Narrower Loss

Positive
Nov 9, 2026

On November 9, 2026, Orthofix reported third-quarter net sales of $207.9 million, up 1% year over year, while its net loss narrowed to $6.1 million and adjusted EBITDA rose to $26.0 million. Growth in Limb Reconstruction and Therapeutic Solutions off...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 11, 2026